373 cases have been filed with the Police/Courts including cases filed for issuing/publishing advertisements in violation of the provisions of the Act.

A National Inspection and Monitoring Committee has also been set up to keep a constant watch on all States and UTs for implementation of the PNDT Act and compliance of the directions of the Supreme Court of India. The committee makes surprise visits to clinics all over India to oversee the implementation of the law.

Besides, various activities are being undertaken regularly for creating public awareness about the provisions of the PNDT Act through Government media *viz.* Radio, TV and other media units. Various stations of AIR are broadcasting spots, group discussions, talks and panel discussions on PNDT Act in various languages.

Efficacy of contraceptive RISUG

*377. DR. C. NARAYANA REDDY: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that the male injectible contraceptive RISUG is under the threat of ban;

(b) whether it is also a fact that premier hospitals in India have given a clean chit to the drug; and

(c) if so, whether Government would examine the efficacy of the new drug?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI SHATRUGHAN SINHA): (a) to (c) The Male injectible contraceptive RISUG is under clinical evaluation.

Limited Phase III Clinical Trial aiming to enroll 150 volunteers for intravasal injection of male contraceptive RISUG is on going at 3 centres at Delhi. 141 healthy volunteers have been enrolled. Data on 63 cases who had completed 6 months of treatment at these three centres revealed four method failure; presence of albumin in urine in 6 cases; and 75% of the subjects experienced scrotal swelling and pain for a period over one month. Semen morphology analysis revealed presence of few abnormal sperms, which may fertilize the ovum leading to genetically defective child or abortion in the late pregnancy.

The monitoring committee appointed by the Department of Family Welfare, Ministry of Health and Family Welfare evaluated the progress of the ongoing limited Phase III clinical trial. The committee in consultation with Toxicological Review Panel of Indian Council of Medical Research recommended that no new subjects should be recruited and all the 141 subjects who have been already recruited, should be followed up for 6 months and evaluation will be reviewed by the panel.

It may also be mentioned that there is no threat of ban on the use of RISUG as the trial is under restricted Phase III Clinical Trial which is on-going, and the period of the trial has been extended till April, 2003.

Achievement of production target by PSUs

†*378. SHRI RAJIV RANJAN SINGH 'LALAN':
SHRI KAPIL SIBAL:

Will the Minister of HEAVY INDUSTRIES AND PUBLIC ENTERPRISES be pleased to state:

(a) whether it is a fact that only 5 industrial establishments out of 46 industrial establishments under his Ministry have achieved their production target during the first six months of the current financial year;

(b) if not, the details in this regard;

(c) the names of such PSUs which failed to achieve their production target during the said period; and

(d) the reasons for less production as compared to the target?

THE MINISTER OF HEAVY INDUSTRIES AND PUBLIC ENTERPRISES (SHRI BALASAHEB VIKHE PATIL): (a) and (b) There are 49 Public Sector Undertakings (PSUs) under the Department of Heavy Industry and out of these, 5 Industrial establishments have achieved their production target during first six months of the current financial year.

(c) The names of the 32 Public Sector Undertakings, which have not been able to achieve their production target during the first six months of the current financial year is given below:—

†*Original notice of the question was received in Hindi.*